From the November 2024 issue of DOTmed Equipment Classifieds magazine
Bot Image, Inc. Announces Growing Acceptance of its Prostate Cancer Screening, Detection, Diagnosis, Lesion Segmentation-Classification, and 3D presentation Software.
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (www.botimageai.com), continues to demonstrate, through its growing partnerships in the radiology and urology communities, that its novel Prostate AI Software with 3D prostate tumor modeling of detected lesions, is improving the standard of care while reducing physician workload as well as costs. These cost reductions can occur through reduction of false positives, their unwarranted procedures, and earlier cancer detection. Note that it is also reimbursable by Medicare and United Healthcare.
Bot Image’s artificial intelligence software, ProstatID®, received FDA clearance June 23, 2022, for its software outputs generated from interpretation of prostate MRIs. From the 510(k) Summary:
Output of the device includes the {3D} volume of the prostate and locations, as well as the extent of suspect lesions, with index scores indicating the likelihood that cancer is present, as well as an exam score by way of PI-RADs interpretation suggestion.
“These outputs were created by the inventors for the specific purposes of presenting an entire 3D view of the prostate with 3D lesions enclosed in order to provide physicians the ‘big picture’ of the patient’s extent and aggressiveness of disease. These outputs also provide an excellent tool for cognitive targeting if urologist lack Fusion Guidance Systems” said Dr. Randall Jones, D.E. (PhD, MBA), CEO of Bot Image. “We’re very excited about working with a growing number of such system manufacturers to merge our unique detection/classification technology with their 3D guidance platforms; so stay tuned for new announcements”.
Dr. Eric M Walser, MD John Sealy Distinguished Chairman and Professor of Radiology at University of Texas Medical Branch, Galveston, Texas added: “ProstatID allows radiologists a three-dimensional view of the relevant findings synthesized from the hundreds of images obtained during multiparametric prostate MRI. This map not only improves diagnosis but also guides the proceduralist during biopsies to target suitable areas and minimize overdiagnosis of clinically insignificant lesions.”
Dr. D. Russell Locke, MD of Vantage Urologic Institute stated, “In my practice, I have seamlessly integrated ProstatID's 3D outputs into cognitive biopsies, surpassing the limitations of traditional fusion systems, ensuring precise alignment and optimal treatment guidance.”
Make an appointment to visit us in our business suite and see a hands-on demonstration at RSNA; or for more information, please contact mjones@botimageai.com or ppfeiffer@botimageai.com and visit
Bot Image.
